U.S. Markets closed
  • S&P 500

    4,536.19
    +16.56 (+0.37%)
     
  • Dow 30

    35,609.34
    +152.03 (+0.43%)
     
  • Nasdaq

    15,121.68
    -7.41 (-0.05%)
     
  • Russell 2000

    2,289.77
    +13.85 (+0.61%)
     
  • Gold

    1,782.80
    +12.30 (+0.69%)
     
  • EUR/USD

    1.1656
    +0.0019 (+0.1632%)
     
  • 10-Yr Bond

    1.6360
    +0.0010 (+0.06%)
     
  • Vix

    15.49
    -0.21 (-1.34%)
     
  • GBP/USD

    1.3819
    +0.0026 (+0.1866%)
     
  • USD/JPY

    114.2970
    -0.0630 (-0.0551%)
     
  • BTC-USD

    65,898.76
    +2,068.48 (+3.24%)
     
  • CMC Crypto 200

    1,538.50
    +57.70 (+3.90%)
     
  • FTSE 100

    7,223.10
    +5.57 (+0.08%)
     
  • Nikkei 225

    29,255.55
    +40.03 (+0.14%)
     

US Medicare Starts Coverage Policy Review For Biogen's Aduhelm

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The U.S. government started a review process for national Medicare coverage of Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug, Aduhelm.

  • The Centers for Medicare & Medicaid Services expects to give a proposed decision within six months and a final decision within nine months.

  • Aduhelm is priced at $56,000 per year, which could represent significant spending for the government's Medicare program for people aged 65 and older.

  • The review will include an analysis of published clinical studies and medical society guidelines, as well as two public hearings later this month to assess the therapy's benefits.

  • Last week, the FDA revised its prescribing recommendations for Aduhelm amid criticism that its initial approval applied to all Alzheimer's patients rather than a narrower group in which the Company conducted trials.

  • Also, FDA Acting Commissioner Janet Woodcock asked for a federal investigation into meetings between agency staff and Biogen executives before the approval decision.

  • Price Action: BIIB shares are up 1.6% at $354.76 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.